Abstract: HepatologyVolume 35, Issue 1 p. 224-231 Special ArticleFree Access New therapeutic strategies for hepatitis C Adrian M. Di Bisceglie M.D., Corresponding Author Adrian M. Di Bisceglie M.D. [email protected] Saint Louis University, St. Louis MODivision of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, 3635 Vista Avenue, St. Louis, MO 63110. fax: 314-577-8125.===Search for more papers by this authorJohn McHutchison, John McHutchison Scripps Clinic, La Jolla, CASearch for more papers by this authorCharles M. Rice, Charles M. Rice The Rockefeller University, New York, NYSearch for more papers by this author Adrian M. Di Bisceglie M.D., Corresponding Author Adrian M. Di Bisceglie M.D. [email protected] Saint Louis University, St. Louis MODivision of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, 3635 Vista Avenue, St. Louis, MO 63110. fax: 314-577-8125.===Search for more papers by this authorJohn McHutchison, John McHutchison Scripps Clinic, La Jolla, CASearch for more papers by this authorCharles M. Rice, Charles M. Rice The Rockefeller University, New York, NYSearch for more papers by this author First published: 30 December 2003 https://doi.org/10.1053/jhep.2002.30531Citations: 126AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Wasley A, Alter MJ. Epidemiology of hepatitis C: Geographic differences and temporal trends. Semin Liver Dis 2000; 20: 1– 13.MEDLINE 2 Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology 2000; 31: 1014– 1018.MEDLINE 3 Keeffe EB. Liver transplantation: current status and novel approaches to liver replacement. Gastroenterology 2001; 120: 749– 762.MEDLINE 4 Liang TJ, Thomson M. Molecular biology of hepatitis C virus. In, TJ Liang, JH Hoofnagle, eds. Hepatitis C. San Diego: Academic Press, 2000; 1– 24. 5 Rijnbrand R, Bredenbeek PJ, Haasnoot PC, Kieft JS, Spaan WJ, Lemon SM. The influence of downstream protein-coding sequence on internal ribosome entry on hepatitis C virus and other flavivirus RNAs. RNA 2001; 7: 585– 597.MEDLINE 6 Walewski JL, Keller TR, Stump DD, Branch AD. Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame. RNA 2001; 7: 710– 721.MEDLINE 7 Xu Z, Choi J, Yen TS, Lu W, Strohecker A, Govindarajan S, Chien D, Selby MJ, Ou, J. Synthesis of a novel hepatitis C virus protein by ribosomal frameshift. EMBO J 2001; 20: 3840– 3848.MEDLINE 8 McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485– 1492.MEDLINE 9 Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288: 339– 344.MEDLINE 10 Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103– 107.MEDLINE 11 Hadlock KG, Lanford RE, Perkins S, Rowe J, Yang Q, Levy S, Pileri P, Abrignani S, Foung SK. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol 2000; 74: 10407– 10416.MEDLINE 12 Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110– 113.MEDLINE 13 Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290: 1972– 1974.MEDLINE 14 Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, Addison WR, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927– 933.MEDLINE 15 Forns X, Thimme R, Govindarajan S, Emerson SU, Purcell RH, Chisari FV, Bukh J. Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc Natl Acad Sci U S A 2000; 97: 13318– 13323.MEDLINE 16 Bassett SE, Guerra B, Brasky K, Miskovsky E, Houghton M, Klimpel GR, Lanford RE. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 2001; 33: 1479– 1487.MEDLINE 17 Weiner AJ, Paliard X, Selby MJ, Medina-Selby A, Coit D, Nguyen S, Kansopon J, et al. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross- protective immunity. J Virol 2001; 75: 7142– 7148.MEDLINE 18 Bukh J, Apgar CL, Yanagi M. Toward a surrogate model for hepatitis C virus: an infectious molecular clone of the GB virus-B hepatitis agent. Virology 1999; 262: 470– 478.MEDLINE 19 He XS, Rehermann B, Boisvert J, Mumm J, Maecker HT, Roederer M, Wright TL, et al. Direct functional analysis of epitope-specific CD8+ T cells in peripheral blood. Viral Immunology 2001; 14: 59– 69.MEDLINE 20 Seeff LB, Zimmerman HJ, Wright EC, Finkelstein JD, Garcia-Pont P, Greenlee HB, Dietz AA, et al. A randomized, double blind controlled trial of the efficacy of immune serum globulin for the prevention of post-transfusion hepatitis. A Veterans Administration cooperative study. Gastroenterology 1977; 72: 111– 121.MEDLINE 21 Sanchez-Quijano A, Pineda JA, Lissen E, Leal M, Diaz-Torres MA, Garcia De Pesquera F, Rivera F, et al. Prevention of post-transfusion non-A, non-B hepatitis by non-specific immunoglobulin in heart surgery patients. Lancet 1988; 1: 1245– 1249.MEDLINE 22 Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999; 19(Suppl 1): 67– 75.MEDLINE 23 Glue P, Fang JWS, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S. Pegylated interferon-α2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000; 68: 556– 567.MEDLINE 24 Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai M-Y, Gane E, O'Grady J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666– 1672.MEDLINE 25 Heathcote EJ, Shiffman ML, Cooksley WGE, Dusheiko GM, Lee SS, Balart L, Reindollar R, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673– 1680.MEDLINE 26 Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, et al. A randomized, double blind trial comparing PEGylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395– 403.MEDLINE 27 Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958– 965.MEDLINE 28 Fried MW, Shiffman ML, Reddy K, Smith C, Marino G, Goncales F, Haeussinger D, et al. Pegylated (40 kDa) interferon alfa-2a (PEGASYS) in combination with ribavirin: efficacy and safety results from a phase II, randomized, actively-controlled, multicenter study [Abstract]. Gastroenterology 2001; 120: A– 55. 29 Tan SL, Katze MG. How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. Virology 2001; 284: 1– 12.MEDLINE 30 Patterson JL, Fernandez-Larson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990; 12: 1139– 1146.MEDLINE 31 Crotty S, Cameron CE, Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A 2001; 98: 6895– 6900.MEDLINE 32 Tam RC, Pai B, Bard J, Lim C, Averett DR, Phan UT, Milovanovic T. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J Hepatol 1999; 30: 376– 382.MEDLINE 33 Wakita T, Moradpour D, Tokushihge K, Wands JR. Antiviral effects of antisense RNA on hepatitis C virus RNA translation and expression. J Med Virol 1999; 57: 217– 222.MEDLINE 34 Usman N. Blatt LM. Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. J Clin Invest 2000; 106: 1197– 1202.MEDLINE 35 Yao N, Reichert P, Taremi SS, Prosise WW, Weber PC. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 1999; 7: 1353– 1363.MEDLINE 36 Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struc Biol 1999; 6: 937– 943. 37 Oh J-W, Ito T, Lai MMC. A recombinant hepatitis C virus RNA-dependent RNA polymerase capable of copying the full-length viral RNA. J Virol 1999; 73: 7694– 7702.MEDLINE 38 Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, Ferreira-Gonzalez A, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999; 117: 1164– 1172.MEDLINE 39 Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, et al. Ribavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 123: 897– 903. 40 Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000; 118: 655– 660.MEDLINE Citing Literature Volume35, Issue1January 2002Pages 224-231 ReferencesRelatedInformation